Main issue in my mind is not the anti-competitive elements that...

Main issue in my mind is not the anti-competitive elements that are to be investigated but the possible destructive element facing the Australian owned pharmaceutical manufacturing industry.

Aspen will want to rationalise the manufacturing operations (they won't want to manufacture any similar competing generic products in more than one location). They will also import products from their overseas operations and source some of their generics from their major shareholder Glaxo (19%).

Bad news for Australian Manufacturing again if the deal goes through.

I support saving the Company as a WHOLE......Pharmacists get behind Sigma and Australian owned manufacturing.